The compound is being developed to block a type of enzyme that allows cancer cells to divide and spread and normal cells to be turned into cancer cells, a Vertex spokesman, Michael Partridge, said.
Therapeutics are being developed to block TGF-β signaling.
For moderate-to-severe psoriasis, effective biologic therapies have been developed to block specific cytokines (e.g., etanercept) or interfere with T-cell activation (e.g., efalizumab).
Several chemicals, such as Nutlin and MI-219, have been developed to block the interaction between Mdm2 and p53 (Shangary et al., 2008; Vassilev et al., 2004).
Many types of inhibitors (i.e. antibodies, peptides, small molecules) have been developed to block ICAM-1/LFA-1 interandionsomend sofe of these molecules have reached clinical trials.
Recently, a variety of tissue engineering constructs have been developed to block the contraction and scar formation mechanisms of repair and induce regeneration following injury.
Various therapeutic approaches including monoclonal antibodies (mAbs) have been developed to block Her2 activity to combat tumor growth (Keler et al. 1997; Ben-Kasus et al. 2009; Vasconcellos et al. 2013).
Recently, a variety of tissue-engineering constructs have been developed to block the contraction and scar formation mechanisms of repair, and to induce regeneration following injury with similar mechanisms of action observed for both the skin and peripheral nervous system (PNS).
